Pharmaniaga supplies additional 6m doses of Sinovac to MOH

by TMR / pic by BERNAMA

PHARMANIAGA Bhd will supply and distribute an additional six million doses of Sinovac COVID-19 vaccine to the Ministry of Health (MOH), upon receiving Letter of Acceptance (LoA) issued by the ministry.

In a statement today the company said this is an addition to the 2 million doses of Sinovac COVID-19 ordered by MOH on 26 July 2021.

The LoA was signed by Minister of Health Datuk Seri Dr Adham Baba representing MOH, while Pharmaniaga was represented by its Group Managing Director Datuk Zulkarnain Md Eusope.

“On 16 July 2021, Pharmaniaga successfully completed its obligation to supply 12.4 million doses of Sinovac COVID-19 vaccine to the Federal Government, 4.5 months ahead of the contract schedule. This LoA will increase the total accumulated supply of Sinovac COVID-19 vaccine for National COVID-19 Immunisation Programme (NIP) to 20.4 million doses,” said Pharmaniaga.

The additional 6 million doses are a combination of both fill and finish vaccines manufactured by its high-tech plant Pharmaniaga LifeScience Sdn Bhd (PLS), and finished vaccines imported from China.

The LoA obliges Pharmaniaga to start supplying the vaccines immediately and to be fulfilled by the end of August 2021.

“We are honoured and grateful for the trust given by the Government to continue our supply and distribution of Sinovac COVID-19 vaccine in order to help maintain the current high vaccination rate momentum.

“Pharmaniaga’s capability to supply large quantities of vaccine in the shortest time was further proven by the completion of 2 million additional orders made at the end of July 2021. We are working hard to ensure the new order of 6 million doses will be fulfilled on time,” said Zulkarnain.

He added the recent increase in capacity of PLS plant to produce 4 million doses a month as well as enlarged capacity by Sinovac plant in China, Pharmaniaga is able to ensure an effective provision and distribution of the additional supply of Sinovac COVID-19 vaccine to MOH without disrupting our existing vaccine supplies to the state governments and the private sector.